We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Gene therapy could help obese kids avoid health problems associated with excess weight, including arthritis, a new study ...
Enrollment in a 2025 Medicare plan opened for beneficiaries today. News outlets focus on an array of changes that could lead to "benefit disruption" that consumers should know about, in particular ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback